Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening.
Duchenne muscular dystrophy (DMD) is a devastating muscle wasting disease caused by mutations in dystrophin, a muscle cytoskeletal protein. Utrophin is a homologue of dystrophin that can functionally compensate for its absence when expressed at increased levels in the myofibre, as shown by studies i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3197614?pdf=render |
| _version_ | 1819161983954452480 |
|---|---|
| author | Catherine Moorwood Olga Lozynska Neha Suri Andrew D Napper Scott L Diamond Tejvir S Khurana |
| author_facet | Catherine Moorwood Olga Lozynska Neha Suri Andrew D Napper Scott L Diamond Tejvir S Khurana |
| author_sort | Catherine Moorwood |
| collection | DOAJ |
| description | Duchenne muscular dystrophy (DMD) is a devastating muscle wasting disease caused by mutations in dystrophin, a muscle cytoskeletal protein. Utrophin is a homologue of dystrophin that can functionally compensate for its absence when expressed at increased levels in the myofibre, as shown by studies in dystrophin-deficient mice. Utrophin upregulation is therefore a promising therapeutic approach for DMD. The use of a small, drug-like molecule to achieve utrophin upregulation offers obvious advantages in terms of delivery and bioavailability. Furthermore, much of the time and expense involved in the development of a new drug can be eliminated by screening molecules that are already approved for clinical use.We developed and validated a cell-based, high-throughput screening assay for utrophin promoter activation, and used it to screen the Prestwick Chemical Library of marketed drugs and natural compounds. Initial screening produced 20 hit molecules, 14 of which exhibited dose-dependent activation of the utrophin promoter and were confirmed as hits. Independent validation demonstrated that one of these compounds, nabumetone, is able to upregulate endogenous utrophin mRNA and protein, in C2C12 muscle cells.We have developed a cell-based, high-throughput screening utrophin promoter assay. Using this assay, we identified and validated a utrophin promoter-activating drug, nabumetone, for which pharmacokinetics and safety in humans are already well described, and which represents a lead compound for utrophin upregulation as a therapy for DMD. |
| first_indexed | 2024-12-22T17:21:01Z |
| format | Article |
| id | doaj.art-3195a3450c9d4923b6df78d8c63f87ee |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T17:21:01Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3195a3450c9d4923b6df78d8c63f87ee2022-12-21T18:18:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01610e2616910.1371/journal.pone.0026169Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening.Catherine MoorwoodOlga LozynskaNeha SuriAndrew D NapperScott L DiamondTejvir S KhuranaDuchenne muscular dystrophy (DMD) is a devastating muscle wasting disease caused by mutations in dystrophin, a muscle cytoskeletal protein. Utrophin is a homologue of dystrophin that can functionally compensate for its absence when expressed at increased levels in the myofibre, as shown by studies in dystrophin-deficient mice. Utrophin upregulation is therefore a promising therapeutic approach for DMD. The use of a small, drug-like molecule to achieve utrophin upregulation offers obvious advantages in terms of delivery and bioavailability. Furthermore, much of the time and expense involved in the development of a new drug can be eliminated by screening molecules that are already approved for clinical use.We developed and validated a cell-based, high-throughput screening assay for utrophin promoter activation, and used it to screen the Prestwick Chemical Library of marketed drugs and natural compounds. Initial screening produced 20 hit molecules, 14 of which exhibited dose-dependent activation of the utrophin promoter and were confirmed as hits. Independent validation demonstrated that one of these compounds, nabumetone, is able to upregulate endogenous utrophin mRNA and protein, in C2C12 muscle cells.We have developed a cell-based, high-throughput screening utrophin promoter assay. Using this assay, we identified and validated a utrophin promoter-activating drug, nabumetone, for which pharmacokinetics and safety in humans are already well described, and which represents a lead compound for utrophin upregulation as a therapy for DMD.http://europepmc.org/articles/PMC3197614?pdf=render |
| spellingShingle | Catherine Moorwood Olga Lozynska Neha Suri Andrew D Napper Scott L Diamond Tejvir S Khurana Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PLoS ONE |
| title | Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. |
| title_full | Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. |
| title_fullStr | Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. |
| title_full_unstemmed | Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. |
| title_short | Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. |
| title_sort | drug discovery for duchenne muscular dystrophy via utrophin promoter activation screening |
| url | http://europepmc.org/articles/PMC3197614?pdf=render |
| work_keys_str_mv | AT catherinemoorwood drugdiscoveryforduchennemusculardystrophyviautrophinpromoteractivationscreening AT olgalozynska drugdiscoveryforduchennemusculardystrophyviautrophinpromoteractivationscreening AT nehasuri drugdiscoveryforduchennemusculardystrophyviautrophinpromoteractivationscreening AT andrewdnapper drugdiscoveryforduchennemusculardystrophyviautrophinpromoteractivationscreening AT scottldiamond drugdiscoveryforduchennemusculardystrophyviautrophinpromoteractivationscreening AT tejvirskhurana drugdiscoveryforduchennemusculardystrophyviautrophinpromoteractivationscreening |